Laura K. Bianchi, M.D.

Laura K. Bianchi, M.D.

Laura K. Bianchi, M.D.

Log into NorthShoreConnect

Profile

Conditions & Procedures

Conditions

Colon Polyps, Colorectal Cancer, Inherited Colorectal Cancer Syndromes

Procedures

Chromoendoscopy, Colonoscopy, Esophagogastroduodenoscopy (EGD), Flexible Sigmoidoscopy, Percutaneous Endoscopic Gastrostomy (PEG), Upper Endoscopy, Variceal and Non Variceal Hemostasis

General Information

Gender

Female

Affiliation

NorthShore Medical Group

Expertise

Colorectal Cancer Prevention, Colon Polyps, Genetics of Colorectal Cancer

Academic Rank

Clinical Assistant Professor

Languages

English

Board Certified

Gastroenterology, Internal Medicine

Education, Training & Fellowships

Medical School

Northwestern Feinberg School of Medicine, 2001

Internship

Northwestern Feinberg School of Medicine, 2002

Residency

Northwestern Feinberg School of Medicine, 2004

Fellowship

Cleveland Clinic Foundation, 2007

Locations

A

NorthShore Medical Group

1000 Central St.
Suite 615
Evanston, IL 60201
847.657.1900 847.570.1534 fax Get Directions This location is wheelchair accessible.

Insurance

For behavioral health services, please confirm participation with your insurance company or provider.

2017 Exchange Plans (Individuals)

 
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Ambetter Insured By Celtic
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Basic PPO A Multi-State Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Choice Preferred PPO (All Plans)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue FocusCare HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Precision HMO (All Plans)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Blue Premier PPO A Multi-State Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Solution PPO A Multi-State Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield BlueCare Direct with Advocate HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Cigna Connect HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Cigna Connect HSA
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 

Off Exchange Plans (Individuals)

 
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Bronze Deductible Only HSA Eligible Savings Plus OAMC PD
Not Available In 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Leap Everday Value Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Aetna Leap Everyday Carelink Centegra Health System
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Aetna Savings Plus OAMC PD (All Metal Tiers)
Not Available In 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Whole Health Chicago (All Metal Tiers)
Not available for 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Whole Health Chicago Bronze Deductible Only HSA Eligible
Not available for 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Ambetter Insured By Celtic
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Choice Preferred PPO (All Plans)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Choice Preferred Security PPO 100
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Cross Blue Premier 101 Multi-State Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Cross Blue Shield Basic 103 Multi-State Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Precision HMO (all plans)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Blue Precision Platinum HMO 104
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield BlueCare Direct with Advocate
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Solution 102 Multi-State Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Coventry $15 Copay: Silver & Gold
Not Available In 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Coventry Bronze $10 Copay Carelink St. John's
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Coventry Bronze $15 Copay Carelink St. John's
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Coventry Bronze $20 Copay
Not Available In 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Coventry Bronze Deductible Only HSA Eligible
Not Available In 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Harken Health - an Affiliate of United Healthcare
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Health Alliance HMO (All Metal Tiers)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Health Alliance POS (All Metal Tiers)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Health Alliance PPO (All Metal Tiers)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Humana Chicago HMOx (All Metal Tiers)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Humana Illinois HMOx
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
United Health One Golden Rule
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Compass (All Plans)
Not Available In 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 

Employer Sponsored Plans

 
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Choice POS II
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Health Network Only
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Managed Choice
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Network Options
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Open Access Aetna Select
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Open Access Managed Choice
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Open Choice PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Savings Plus
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Select
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Sub- Cofinity
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Sub- First Health
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Traditional Choice-Indemnity Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Whole Health Chicago (All Metal Tiers)
For employers with 2-50 employees
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Beechstreet PPO Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Blue Advantage HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Blue Choice Options PPO (All Metal Tiers)
Participating in Tier 2, there may be higher out of pocket costs
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Blue Choice Preferred PPO (All Plans)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Choice Select PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Choice Select Value Choice
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Blue Distinction Total Care Benefit Differentail
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Blue PPO (All Metal Tiers)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Blue Precision HMO Plans (All Metal Tiers)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield BlueCare Direct (All Metal Tiers)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield BlueEdge HSA and BlueEdge HCA
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield BluePrint
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Community Participating Option
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield HMOI
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield PPO Value Choice
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Exclusive Provider Organization EPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Great West Healthcare (GWH) Cigna Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna HMO Open Access
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna HMO Open Access POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna HMO POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical Indemnity
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical LocalPlus
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical LocalPlus In-Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical Network POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical Open Access Plus (OAP)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical Open Access Plus (OAP) In-Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna Medical Open Access POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cofinity PPO (an Aetna Company)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Coventry Consumer Choices (C3)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Coventry HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Coventry POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Coventry PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Galaxy Health Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Harken Health
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Health Alliance HMO, PPO, POS, POS-C
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Health Link HMO
If Unicare Affiliate logo present on card
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Health Link PPO
If Unicare Affiliate logo present on card
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Health Link-Open Access I, II, III
If Unicare Affiliate logo present on card
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Healthcare's Finest Network- FHN 10 & 20
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Healthcare's Finest Network- FHN Platinum
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Healthcare's Finest Network- HFN Community Health Connect
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Healthcare's Finest Network- HFN Community Health Connect Elite
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Healthcare's Finest Network- HFN Community Health Connect Premiere
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Healthcare's Finest Network- HFN-ID
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Advocate Centered EPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Humana Advocate Centered HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Humana Choice POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Classic Plan (Traditional Indemnity Plan)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Coinsurance: NPOS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Coinsurance: PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Coinsurance:HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Condell Custom PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Humana Copay: HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Copay: NPOS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Copay: PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana COT National POS-Open Access
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Edward- Elmhurst Value HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Humana Edward-Elmhurst Advantage HSA/Choice PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Humana High-deductible plans (HDHP) HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana High-deductible plans (HDHP) National point of service (NPOS)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana High-deductible plans (HDHP) PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Illinois Coordinated Care
Available In 2017
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Level Funded Premium
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana NorthShore Complete Care
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Self Funding: Administrative Services Only (ASO)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Self-Funding: Level Funded Premium (LFP)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Self-Funding: Minimum Premium (MP)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Self-Funding: Stop Loss Insurance
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Simplicity (HMO, POS, PPO)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Total Health (100 or more employees)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Multiplan/ PHCS- Health EOS Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Multiplan/ PHCS- MultiPlan Complementary
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Multiplan/ PHCS- MultiPlan Limited Benefit Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Multiplan/ PHCS- MultiPlan Practitioner Only
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Multiplan/ PHCS- MultiPlan Shared Savings
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
Multiplan/ PHCS- PHCS Healthy Directions
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Multiplan/ PHCS- PHCS Practitioner Only
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Multiplan/ PHCS- PHCS Savility
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Multiplan/ PHCS- ValuePoint by MultiPlan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
NorthShore Employee Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Preferred Network Access
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Preferred Plan- HealthSmart Get Better
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Preferred Plan PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Stratose- National Preferred Provider Network
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
Three Rivers Provider PPO Network (TRPN)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
UniCare HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
UniCare HMO Performance Select
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Unicare PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
UniCare Travel Access
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Health One Golden Rule
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Catalyst
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Charter
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
United Healthcare Choice
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Choice Plus
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Core
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
United Healthcare Heritage
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Multi-Choice
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Navigate and Navigate Plus
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
United Healthcare Options Non-Differential PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Options PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Tiered Benefits
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 

Medicaid

 
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Better Health FHP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
Aetna Better Health ICP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
Blue Cross Blue Shield Community FHP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Community ICP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Cigna HealthSpring ICP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Community Care Alliance- ICP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Family Health Network- FHP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
Harmony/WellCare FHP Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
Humana ICP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Illinicare Family Health Plan (FHP/ACA)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Illinicare ICP
Primary Care- Current Patients Only
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Illinois Department of Public Aid (IDPA)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Meridian FHP/ACA Expansion
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Meridian ICP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Molina ICP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Next Level ACA/FHP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 

Medicare Advantage Plans

 
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Medicare (SM) Plan (HMO)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Medicare (SM) Plan (PPO)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Medicare Advantage Group Plans
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Medicare Connect Plus (PPO)/PPO Connect Plus
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Medicare Standard Plan (PPO)/PPO Standard Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Medicare Value Plan (HMO)/HMO Value
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Medicare Value Plan (PPO)/PPO Value Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Traditional Choice Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Medicare Advantage Basic HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Medicare Advantage Basic Plus HMO-POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Medicare Advantage Choice Plus PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Medicare Advantage Choice Premier PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Blue Cross Blue Shield Medicare Advantage Premier Plus HMO-POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Cigna-HealthSpring Advantage HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna-HealthSpring Premier HMO-POS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna-HealthSpring Primary HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna-HealthSpring TotalCare HMO-SNP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Community Care Alliance Complete HMO-D-SNP
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Community Care Alliance HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Harmony/WellCare Access (HMO-SNP)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Harmony/WellCare Choice (HMO-POS)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Harmony/WellCare Health Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Harmony/WellCare RX (HMO)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Harmony/WellCare Value (HMO-POS)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Harmony/WellCare-Medicare HMO Plans
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Harmony/WellCare-Medicare Special Needs Plans
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Humana Choice PPO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Community HMO Diabetes and Heart (SNP Program)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Gold Plus HMO
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana Gold Plus PFFS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Meridian Medicare Advantage
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Molina Medicare Advantage
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
United Healthcare - AARP Medicare Complete
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare AARP Medicare Complete Access
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
United Healthcare- AARP Medicare Complete Plus (HMO-POS)
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
United Healthcare Medicare Advantage Focus
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
United Healthcare- Medicare Solutions/Medicare Advantage
PRIMARY CARE
SPECIALTY CARE
HOSPITALS

Medicare Medicaid Alignment Initiative (MMAI) Plans

 
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Aetna Better Health MMAI
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Community MLTSS/LTSS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Blue Cross Blue Shield Community MMAI
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Cigna-HealthSpring MMAI
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Humana MMAI
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Illinicare MLTSS/LTSS
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 
Illinicare MMAI
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Meridian MMAI
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Molina MMAI
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
 

Medicare Supplemental Plans

 
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
Medicare Supplemental Plans
These plans are secondary to Traditional Medicare; we accept all supplemental plans. Please confirm your coverage benefits with your supplemental carrier.
PRIMARY CARE
SPECIALTY CARE
HOSPITALS

Coverage For Active Military

 
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
TRICARE For Life
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Prime
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Prime Overseas
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Prime Remote
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Prime Remote Overseas
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Reserve Select
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Retired Reserve
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Standard and Extra
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Standard Overseas
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE US Family Plan
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 
TRICARE Young Adult
PRIMARY CARE
SPECIALTY CARE
HOSPITALS
 
 

Publications

  • Rectal Optical Markers for In Vivo Risk Stratification of Premalignant Colorectal Lesions.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Oct 01

    Authors: Radosevich AJ, Mutyal NN, Eshein A, Nguyen TQ, Gould B, Rogers JD, Goldberg MJ, Bianchi LK, Yen EF, Konda V, Rex DK, Van Dam J, Backman V, Roy HK
    Abstract
    Colorectal cancer remains the second leading cause of cancer deaths in the United States despite being eminently preventable by colonoscopy via removal of premalignant adenomas. In order to more effectively reduce colorectal cancer mortality, improved screening paradigms are needed. Our group pioneered the use of low-coherence enhanced backscattering (LEBS) spectroscopy to detect the presence of adenomas throughout the colon via optical interrogation of the rectal mucosa. In a previous ex vivo biopsy study of 219 patients, LEBS demonstrated excellent diagnostic potential with 89.5% accuracy for advanced adenomas. The objective of the current cross-sectional study is to assess the viability of rectal LEBS in vivo.
    Measurements from 619 patients were taken using a minimally invasive 3.4-mm diameter LEBS probe introduced into the rectum via anoscope or direct insertion, requiring approximately 1 minute from probe insertion to withdrawal. The diagnostic LEBS marker was formed as a logistic regression of the optical reduced scattering coefficient [Formula: see text] and mass density distribution factor D.
    The rectal LEBS marker was significantly altered in patients harboring advanced adenomas and multiple non-advanced adenomas throughout the colon. Blinded and cross-validated test performance characteristics showed 88% sensitivity to advanced adenomas, 71% sensitivity to multiple non-advanced adenomas, and 72% specificity in the validation set.
    We demonstrate the viability of in vivo LEBS measurement of histologically normal rectal mucosa to predict the presence of clinically relevant adenomas throughout the colon. The current work represents the next step in the development of rectal LEBS as a tool for colorectal cancer risk stratification.
    PMID: 25991816 [PubMed - as supplied by publisher]
  • Colonic mucosal fatty acid synthase as an early biomarker for colorectal neoplasia: modulation by obesity and gender.

    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2014 Nov

    Authors: Cruz MD, Wali RK, Bianchi LK, Radosevich AJ, Crawford SE, Jepeal L, Goldberg MJ, Weinstein J, Momi N, Roy P, Calderwood AH, Backman V, Roy HK
    Abstract
    We have previously reported that colonic pericryptal microvascular blood flow is augmented in the premalignant colonic epithelium, highlighting the increased metabolic demand of the proliferative epithelium as a marker of field carcinogenesis. However, its molecular basis is unexplored. In this study, we assessed the expression of a regulator of the "lipogenic switch," fatty acid synthase (FASN), in early colon carcinogenesis for its potential biomarker utility for concurrent neoplasia.
    FASN expression (IHC) in the colonic epithelium from azoxymethane and polyposis in rat colon (Pirc) models of colorectal cancer was studied. FASN mRNA expression from endoscopically normal rectal mucosa was evaluated and correlated with colonoscopic findings (pathologic confirmation of neoplasia).
    FASN expression progressively increased from premalignant to malignant stage in the azoxymethane model (1.9- to 2.5-fold; P < 0.0001) and was also higher in the adenomas compared with adjacent uninvolved mucosa (1.8- to 3.4-fold; P < 0.001) in the Pirc model. Furthermore, FASN was significantly overexpressed in rectal biopsies from patients harboring adenomas compared with those with no adenomas. These effects were accentuated in male (∼2-fold) and obese patients (1.4-fold compared with those with body mass index < 30). Overall, the performance of rectal FASN was excellent (AUROC of 0.81).
    FASN is altered in the premalignant colonic mucosa and may serve as a marker for colonic neoplasia present elsewhere. The enhanced effects in men and obesity may have implications for identifying patient subgroups at risk for early-onset neoplasia.
    These findings support the role of rectal FASN expression as a reliable biomarker of colonic neoplasia.
    PMID: 25155760 [PubMed - as supplied by publisher]
  • Spatially resolved optical and ultrastructural properties of colorectal and pancreatic field carcinogenesis observed by inverse spectroscopic optical coherence tomography.

    Journal of biomedical optics 2014 Mar

    Authors: Yi J, Radosevich AJ, Stypula-Cyrus Y, Mutyal NN, Azarin SM, Horcher E, Goldberg MJ, Bianchi LK, Bajaj S, Roy HK, Backman V
    Abstract
    Field carcinogenesis is the initial stage of cancer progression. Understanding field carcinogenesis is valuable for both cancer biology and clinical medicine. Here, we used inverse spectroscopic optical coherence tomography to study colorectal cancer (CRC) and pancreatic cancer (PC) field carcinogenesis. Depth-resolved optical and ultrastructural properties of the mucosa were quantified from histologically normal rectal biopsies from patients with and without colon adenomas (n=85) as well as from histologically normal peri-ampullary duodenal biopsies from patients with and without PC (n=22). Changes in the epithelium and stroma in CRC field carcinogenesis were separately quantified. In both compartments, optical and ultra-structural alterations were consistent. Optical alterations included lower backscattering (μb) and reduced scattering (μs') coefficients and higher anisotropy factor g. Ultrastructurally pronounced alterations were observed at length scales up to ∼450  nm, with the shape of the mass density correlation function having a higher shape factor D, thus implying a shift to larger length scales. Similar alterations were found in the PC field carcinogenesis despite the difference in genetic pathways and etiologies. We further verified that the chromatin clumping in epithelial cells and collagen cross-linking caused D to increase in vitro and could be among the mechanisms responsible for the observed changes in epithelium and stroma, respectively.
    PMID: 24643530 [PubMed - as supplied by publisher]
  • Nanoscale changes in chromatin organization represent the initial steps of tumorigenesis: a transmission electron microscopy study.

    BMC cancer 2014 Mar 14

    Authors: Cherkezyan L, Stypula-Cyrus Y, Subramanian H, White C, Dela Cruz M, Wali RK, Goldberg MJ, Bianchi LK, Roy HK, Backman V
    Abstract
    Nuclear alterations are a well-known manifestation of cancer. However, little is known about the early, microscopically-undetectable stages of malignant transformation. Based on the phenomenon of field cancerization, the tissue in the field of a tumor can be used to identify and study the initiating events of carcinogenesis. Morphological changes in nuclear organization have been implicated in the field of colorectal cancer (CRC), and we hypothesize that characterization of chromatin alterations in the early stages of CRC will provide insight into cancer progression, as well as serve as a biomarker for early detection, risk stratification and prevention.
    For this study we used transmission electron microscopy (TEM) images of nuclei harboring pre-neoplastic CRC alterations in two models: a carcinogen-treated animal model of early CRC, and microscopically normal-appearing tissue in the field of human CRC. We quantify the chromatin arrangement using approaches with two levels of complexity: 1) binary, where chromatin is separated into areas of dense heterochromatin and loose euchromatin, and 2) grey-scale, where the statistics of continuous mass-density distribution within the nucleus is quantified by its spatial correlation function.
    We established an increase in heterochromatin content and clump size, as well as a loss of its characteristic peripheral positioning in microscopically normal pre-neoplastic cell nuclei. Additionally, the analysis of chromatin density showed that its spatial distribution is altered from a fractal to a stretched exponential.
    We characterize quantitatively and qualitatively the nanoscale structural alterations preceding cancer development, which may allow for the establishment of promising new biomarkers for cancer risk stratification and diagnosis. The findings of this study confirm that ultrastructural changes of chromatin in field carcinogenesis represent early neoplastic events leading to the development of well-documented, microscopically detectable hallmarks of cancer.
    PMID: 24629088 [PubMed - as supplied by publisher]
  • Ultrastructural alterations in field carcinogenesis measured by enhanced backscattering spectroscopy.

    Journal of biomedical optics 2013 Sep

    Authors: Radosevich AJ, Mutyal NN, Yi J, Stypula-Cyrus Y, Rogers JD, Goldberg MJ, Bianchi LK, Bajaj S, Roy HK, Backman V
    Abstract
    Optical characterization of biological tissue in field carcinogenesis offers a method with which to study the mechanisms behind early cancer development and the potential to perform clinical diagnosis. Previously, low-coherence enhanced backscattering spectroscopy (LEBS) has demonstrated the ability to discriminate between normal and diseased organs based on measurements of histologically normal-appearing tissue in the field of colorectal (CRC) and pancreatic (PC) cancers. Here, we implement the more comprehensive enhanced backscattering (EBS) spectroscopy to better understand the structural and optical changes which lead to the previous findings. EBS provides high-resolution measurement of the spatial reflectance profile P(rs) between 30 microns and 2.7 mm, where information about nanoscale mass density fluctuations in the mucosa can be quantified. A demonstration of the length-scales at which P(rs) is optimally altered in CRC and PC field carcinogenesis is given and subsequently these changes are related to the tissue's structural composition. Three main conclusions are made. First, the most significant changes in P(rs) occur at short length-scales corresponding to the superficial mucosal layer. Second, these changes are predominantly attributable to a reduction in the presence of subdiffractional structures. Third, similar trends are seen for both cancer types, suggesting a common progression of structural alterations in each.
    PMID: 24008865 [PubMed - as supplied by publisher]
  • Nanocytology of rectal colonocytes to assess risk of colon cancer based on field cancerization.

    Cancer research 2012 Jun 01

    Authors: Damania D, Roy HK, Subramanian H, Weinberg DS, Rex DK, Goldberg MJ, Muldoon J, Cherkezyan L, Zhu Y, Bianchi LK, Shah D, Pradhan P, Borkar M, Lynch H, Backman V
    Abstract
    Developing a minimally invasive and cost-effective prescreening strategy for colon cancer is critical because of the impossibility of conducting colonoscopy on the entire at-risk population. The concept of field carcinogenesis, in which normal-appearing tissue away from a tumor has molecular and, consequently, nano-architectural abnormalities, offers one attractive approach to identify high-risk patients. In this study, we investigated whether the novel imaging technique partial wave spectroscopic (PWS) microscopy could risk-stratify patients harboring precancerous lesions of the colon, using an optically measured biomarker (L(d)) obtained from microscopically normal but nanoscopically altered cells. Rectal epithelial cells were examined from 146 patients, including 72 control patients, 14 patients with diminutive adenomas, 20 patients with nondiminutive/nonadvanced adenomas, 15 patients with advanced adenomas/high-grade dysplasia, 12 patients with genetic mutation leading to Lynch syndrome, and 13 patients with cancer. We found that the L(d) obtained from rectal colonocytes was well correlated with colon tumorigenicity in our patient cohort and in an independent validation set of 39 additional patients. Therefore, our findings suggest that PWS-measured L(d) is an accurate marker of field carcinogenesis. This approach provides a potential prescreening strategy for risk stratification before colonoscopy.
    PMID: 22491589 [PubMed - as supplied by publisher]
  • Sex-specific prevalence of adenomas and colorectal cancer.

    JAMA 2012 Jan 11

    Authors: Yen EF, Pokhrel B, Bianchi LK, Roy HK, Du H, Patel A, Hall CR, Witt BL
    Abstract
    Microscopic colitis is currently considered to harbor no increased risk for colorectal cancer, based on a few small studies with limited long-term follow-up. Our aim was to identify patients with microscopic colitis, and to compare long-term rates of colorectal cancer or adenoma to a control group of patients without microscopic colitis.
    We reviewed the records of patients diagnosed with microscopic colitis, as identified by a hospital-based pathology database from January 2000 to August 2008. Clinical factors, including history of adenoma or adenocarcinoma, and all colonoscopy findings, were recorded. Age and gender-matched patients without microscopic colitis served as the control in a 1:1 fashion.
    A total of 647 patients (153 male: 494 female) were identified with microscopic colitis (MC). Any history of colorectal cancer was detected in 1.92, 1.81, and 4.17% of patients with collagenous colitis (CC), lymphocytic colitis (LC), and controls, respectively (P = 0.095, P = 0.040, P = 0.015 for CC, LC, and all MC, respectively, comparing to controls). Overall, covariate-adjusted risk (odds ratio) of any history of colorectal cancer and colorectal adenoma in MC patients was 0.34 (95% confidence interval [CI] 0.16-0.73, P = 0.006) and 0.52 (95% CI 0.50-0.76, P < 0.0001), respectively. The mean duration of follow-up was 4.63 years, with 147/647 (22.7%) of patients with clinical follow-up >7 years.
    In this case-control study involving a large retrospective cohort, microscopic colitis is negatively associated with the risk for colorectal cancer and adenoma. Further studies are required to determine a temporal relationship between microscopic colitis and the future development of colorectal neoplasia.
    PMID: 22235076 [PubMed - as supplied by publisher]
  • Moving toward personalization of colorectal cancer screening: Comment on "Influence of race and sex on prevalence and recurrence of colon polyps".

    Archives of internal medicine 2010 Jul 12

    Authors: Roy HK, Gomes AJ, Ruderman S, Bianchi LK, Goldberg MJ, Stoyneva V, Rogers JD, Turzhitsky V, Kim Y, Yen E, Jameel M, Bogojevic A, Backman V
    Abstract
    Flexible sigmoidoscopy is a robust, clinically validated, and widely available colorectal cancer screening technique that is currently sanctioned by major guideline organizations. Given that endoscopic visualization is generally limited to the distal third of the colon and women tend to have a proclivity for proximal lesions, the flexible sigmoidoscopy performance is markedly inferior in women than in men. Our group has shown that by using a novel light-scattering approach, we were able to detect an early increase in blood supply (EIBS) in the distal colonic mucosa, which served as a marker of field carcinogenesis and, hence, proximal neoplasia. Therefore, we sought to ascertain whether rectal EIBS would improve flexible sigmoidoscopy, especially in women. A polarization-gated spectroscopy fiber-optic probe was used to assess EIBS in the endoscopically normal rectum (n = 366). When compared with gender-matched neoplasia-free controls, females with advanced proximal neoplasia (n = 10) had a robust (60%; P = 0.002) increase in rectal mucosal oxyhemoglobin content whereas the effect size in males was less marked (33%; P = 0.052). In women, addition of rectal oxyhemoglobin tripled the sensitivity for advanced neoplasia over flexible sigmoidoscopy alone. Indeed, the performance characteristics seemed to be excellent (sensitivity, 100%; specificity, 76.8%; positive predictive value, 32.6%; and negative predictive value, 100%). A variety of nonneoplastic factors were assessed and did not confound the relationship between rectal EIBS and advanced neoplasia. Therefore, using rectal EIBS in combination with flexible sigmoidoscopy mitigated the gender gap and may allow flexible sigmoidoscopy to be considered as a viable colorectal cancer screening test in women.
    PMID: 20625019 [PubMed - as supplied by publisher]

In the News

Nov 2015

Jul 2015

Mar 2014

Social Media